{"prompt": "['2016N277425_03', 'CONFIDENTIAL', '2018N377698_00', '201749', '9.2.', 'Sample Size Considerations', 'The primary endpoint is change from baseline in trough FEV1 at Week 24. As an', 'important aim of the study is to compare UMEC/VI, UMEC and salmeterol with respect', 'to HRQoL the sample size has been calculated to provide sufficient power for the', 'comparison of the primary and secondary endpoint TDI, at Week 24.', 'The sample size calculations use a two-sided 5% significance level and an estimate of', 'between subject standard deviation for TDI of 2.94 units. The estimate of SD is based on', 'DB2113373 [Donohue, 2013], a study which consisted of treatment arms of UMEC/VI', '62.5/25, UMEC 62.5 VI (Vilanterol) 25mcg and placebo and is the value at Day 168 in a', 'subgroup of subjects who were ICS free at screening. Based on these data, 727 evaluable', 'subjects per treatment arm will be required to provide 90% power to detect a statistically', 'significant difference if the true difference is 0.5 units, 1/2 the MCID, between UMEC/VI', 'and UMEC. The smallest observed effect predicted to result in a statistically significant', 'difference between treatment groups is 0.31 units.', 'With this number of evaluable subjects per arm, the study will have >99% power', 'assuming a true treatment difference of 80mL between UMEC/VI and UMEC for trough', 'FEV1 at 24 weeks at the two-sided 5% significance level. This calculation uses a SD for', 'trough FEV1 of 240mL, based on prior results for trials comparing dual bronchodilators', 'versus single bronchodilators (Donohue, 2013; Bateman, 2013). The smallest observed', 'effect predicted to result in a statistically significant difference between treatment groups', 'is 25mL.', 'In order to account a for a 10% withdrawal rate, approximately 808 subjects per', 'treatment arm will be randomised.', '9.2.1.', 'Sample Size Sensitivity', 'The assumption of a SD of 2.94 units for the TDI total score is based on estimates from', 'previous studies. The following table presents the power achieved with the proposed', 'sample size of 727 randomised subjects per arm, should the assumption around the SD of', 'the data change.', 'The actual assumptions used in the sample size calculation are shaded.', 'Endpoint', 'Between', 'Treatment Difference', 'Power', 'subject SD', 'TDI', '2.54', '0.5', '96%', '2.74', '0.5', '94%', '2.94', '0.5', '90%', '3.14', '0.5', '86%', '3.34', '0.5', '81%', '59']['2016N277425_03', 'CONFIDENTIAL', '2018N377698_00', '201749', '9.2.2.', 'Sample Size Re-estimation or Adjustment', 'No sample size re-estimation is planned for this study.', '9.3.', 'Data Analysis Considerations', '9.3.1.', 'Analysis Populations', 'Population', 'Definition / Criteria', 'Analyses Evaluated', 'All', 'All subjects for whom a record exists in the', 'Subject', 'Subjects', 'study database, including screen failures and', 'Disposition', 'Enrolled', 'any subject who was not screened but', 'Reasons for', '(ASE)', 'experienced an SAE between the date of', 'withdrawal prior', 'informed consent and the planned date of the', 'to randomisation', 'Screening visit.', 'Inclusion,', 'exclusion and', 'randomisation', 'criteria deviations', 'SAEs for non-', 'randomised', 'subjects', 'Intent-to-', 'All randomized subjects, excluding those who', 'Study Population', 'treat (ITT)', 'were randomized in error and received at least', 'Efficacy', 'one dose of study medication. A subject who', 'Safety', 'is recorded as a screen or run-in failure and', 'also randomized will be considered to be', 'randomized in error. Any other subject who', 'receives a randomization number will be', 'considered to have been randomized.', 'Displays will be based on the treatment to', 'which the subject was randomized.', 'Intent-to-', 'All subjects in the ITT Population who have', 'Study Population', 'treat ICS', 'not received ICS.', 'Efficacy', 'free (ITT', 'Safety', 'ICS free)', '9.3.2.', 'Interim Analysis', 'No interim analysis is planned for the study.', '9.4.', 'Key Elements of Analysis Plan', 'Treatment Comparisons', 'The primary treatment comparison of UMEC/VI with UMEC will be performed on the', 'ITT population.', '60']\n\n###\n\n", "completion": "END"}